netelixir

‘SC Administration and Immunogenicity Risk; Current Understanding and Future Considerations for Novel Modalities’ In order to focus on the most important considerations for SC product development, developers must have a data-driven understanding of contributing factors to SC and IV immunogenicity (features of the immune response, product attributes, etc.) and correlation to safety/adverse events following SC route of delivery. The Immunogenicity sub-team of the Subcutaneous (SC) Drug Develop...

The Clinical Development & Regulatory Strategy (CDRS) sub-team of the Subcutaneous (SC) Drug Development and Delivery Consortium is excited to announce their upcoming virtual workshop ‘Roadmapping the Clinical and Regulatory Paths of SC Products and Technologies’, sponsored through AAPS (https://subcutaneousconsortium.org/cdrs-workshop-announcement/) In this workshop, taking place February 23rd, we will bring industry professionals, academics, and regulatory experts together to share kno...